FLT3 and acute myeloid leukemia: Nishioka et al. reported in their study that Entinostat induced degradation of FLT3 through the inhibition of the chaperon activity of the heat shock protein 90 in AML cells, suggesting that this inhibitor may be useful for the treatment of AML patients with FLT3 mutations [195].